AnaptysBio Management
Management criteria checks 3/4
AnaptysBio's CEO is Dan Faga, appointed in Mar 2022, has a tenure of 2.67 years. total yearly compensation is $7.46M, comprised of 8.6% salary and 91.4% bonuses, including company stock and options. directly owns 1.32% of the company’s shares, worth $8.50M. The average tenure of the management team and the board of directors is 2.7 years and 3.7 years respectively.
Key information
Dan Faga
Chief executive officer
US$7.5m
Total compensation
| CEO salary percentage | 8.6% |
| CEO tenure | 2.7yrs |
| CEO ownership | 1.3% |
| Management average tenure | 2.7yrs |
| Board average tenure | 3.7yrs |
Recent management updates
Recent updates
AnaptysBio: An Immunology Pipeline-In-A-Pill Company Worth Watching
Nov 21AnaptysBio, Inc. (NASDAQ:ANAB) May Have Run Too Fast Too Soon With Recent 33% Price Plummet
Nov 07
AnaptysBio: Too Risky, Especially After GSK Drops Its Related Programs
Nov 01AnaptysBio: Top-Line AD Data End Of 2024 Could Be Turning Point
Aug 15AnaptysBio: Interesting Prospects, But Wait For The Dip (Rating Downgrade)
Jul 08News Flash: Analysts Just Made A Captivating Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Forecasts
May 22Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates
May 12Does AnaptysBio (NASDAQ:ANAB) Have A Healthy Balance Sheet?
Feb 22Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation
Oct 10AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Trimmed Their Revenue Forecasts By 12%
May 24Is AnaptysBio (NASDAQ:ANAB) In A Good Position To Deliver On Growth Plans?
Apr 27Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation
Jan 10AnaptysBio benefits from results of GSK mid-stage Jemperli combo lung cancer trial
Oct 05Broker Revenue Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging Higher
Sep 14AnaptysBio sells royalties from GSK-partnered Zejula for $45M
Sep 12AnaptysBio (NASDAQ:ANAB) Is In A Good Position To Deliver On Growth Plans
Sep 01AnaptysBio skin condition candidate fails mid-stage trial; shares down 16%
Aug 31AnaptysBio GAAP EPS of -$1.15 misses by $0.14, revenue of $1.21M misses by $4.4M
Aug 08Some AnaptysBio, Inc. (NASDAQ:ANAB) Analysts Just Made A Major Cut To Next Year's Estimates
May 10Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation
Mar 16AnaptysBio's (NASDAQ:ANAB) Performance Is Even Better Than Its Earnings Suggest
Nov 11CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$166m |
| Jun 30 2024 | n/a | n/a | -US$170m |
| Mar 31 2024 | n/a | n/a | -US$163m |
| Dec 31 2023 | US$7m | US$641k | -US$164m |
| Sep 30 2023 | n/a | n/a | -US$148m |
| Jun 30 2023 | n/a | n/a | -US$144m |
| Mar 31 2023 | n/a | n/a | -US$137m |
| Dec 31 2022 | US$25m | US$474k | -US$129m |
| Sep 30 2022 | n/a | n/a | -US$135m |
| Jun 30 2022 | n/a | n/a | -US$108m |
| Mar 31 2022 | n/a | n/a | -US$76m |
| Dec 31 2021 | US$310k | n/a | -US$58m |
Compensation vs Market: Dan's total compensation ($USD7.46M) is above average for companies of similar size in the US market ($USD3.20M).
Compensation vs Earnings: Dan's compensation has been consistent with company performance over the past year.
CEO
Dan Faga (44 yo)
2.7yrs
Tenure
US$7,461,920
Compensation
Mr. Daniel R. Faga, also known as Dan, is Director of Affini-T Therapeutics, Inc. from April 2022. He serves as Director at AnaptysBio, Inc. since November 2021 and is its President and Chief Executive Off...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.7yrs | US$7.46m | 1.32% $ 8.5m | |
| Chief Legal Officer | 6.3yrs | US$2.26m | 0.011% $ 68.6k | |
| Chief Medical Officer | 4.3yrs | US$2.44m | 0.051% $ 326.0k | |
| Chief Financial Officer | 4.3yrs | US$1.81m | 0.016% $ 100.4k | |
| Senior Vice President of Human Resources | 5.1yrs | no data | no data | |
| Senior Vice President of Research | 2.8yrs | no data | no data | |
| Chief Business Officer | less than a year | no data | no data | |
| Senior Vice President of CMC | 1.8yrs | no data | no data | |
| Senior Vice President of Corporate Affairs | less than a year | no data | no data | |
| Senior Vice President of Clinical Operations | less than a year | no data | no data | |
| Senior Vice President of Clinical Development | less than a year | no data | no data |
2.7yrs
Average Tenure
55yo
Average Age
Experienced Management: ANAB's management team is considered experienced (2.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3yrs | US$7.46m | 1.32% $ 8.5m | |
| Independent Chairman of the Board | 1.2yrs | US$338.08k | 0.011% $ 70.6k | |
| Lead Independent Director | 9.4yrs | US$342.38k | 0.0064% $ 41.3k | |
| Independent Director | 9.4yrs | US$335.38k | 0.013% $ 82.6k | |
| Independent Director | 6.7yrs | US$331.88k | 0.0064% $ 41.3k | |
| Independent Director | 3.8yrs | US$318.38k | 0.013% $ 82.6k | |
| Independent Director | 3.6yrs | no data | no data | |
| Independent Director | 7.3yrs | US$338.38k | 0.025% $ 158.8k | |
| Independent Director | 1.6yrs | US$495.60k | 0.015% $ 96.0k | |
| Member of Scientific Advisory Board | 1.8yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
3.7yrs
Average Tenure
61yo
Average Age
Experienced Board: ANAB's board of directors are considered experienced (3.7 years average tenure).